CAJ | 학술논문

1例62岁男性直肠癌术后吻合口复发伴肝转移患者自2012年7月19日起接受西妥昔单抗（第1周：716 mg，第2~34周：447.5 mg；1次/周静脉滴注）单药治疗。2013年3月28日为接受该药第35次治疗入院，实验室检查示血镁水平明显低下（0.35 mmol/ L），其他电解质水平、血生化指标、醛固酮、甲状腺功能和血、尿、大便常规检查均未见异常。复习患者病历资料，显示应用西妥昔单抗后其血镁水平逐渐降低，2013年1月31日降至0.51 mmol/ L。考虑系西妥昔单抗致低镁血症。给予硫酸镁10 ml +0.9%氯化钠注射液500 ml 静脉滴注，1次/ d。应用硫酸镁第3天患者血镁升至0.54 mmol/ L，当日给予西妥昔单抗447.5 mg，患者出院。继续在门诊接受补镁治疗，8 d 后复查，血镁0.82 mmol/ L。
1례62세남성직장암술후문합구복발반간전이환자자2012년7월19일기접수서타석단항（제1주：716 mg，제2~34주：447.5 mg；1차/주정맥적주）단약치료。2013년3월28일위접수해약제35차치료입원，실험실검사시혈미수평명현저하（0.35 mmol/ L），기타전해질수평、혈생화지표、철고동、갑상선공능화혈、뇨、대편상규검사균미견이상。복습환자병력자료，현시응용서타석단항후기혈미수평축점강저，2013년1월31일강지0.51 mmol/ L。고필계서타석단항치저미혈증。급여류산미10 ml +0.9%록화납주사액500 ml 정맥적주，1차/ d。응용류산미제3천환자혈미승지0.54 mmol/ L，당일급여서타석단항447.5 mg，환자출원。계속재문진접수보미치료，8 d 후복사，혈미0.82 mmol/ L。
A 62-year-old male patient received an IV infusion of cetuximab( cycle 1:716 mg, cycle 2-34:447. 5 mg)once weekly since July 19th,2012 for postoperative anastomotic recurrence of rectal cancer and liver metastasis. Blood magnesium was 0. 35 mmol/ L and other electrolyte levels,biochemical indexes,aldosterone level,thyroid function tests,blood routine,urine routine and stool routine tests were normal when he was admitted to hospital on March 28,2013. Review patientsˊ medical records,blood magnesium level was gradually reduced and accompanied with the application of cetuximab, blood magnesium was 0. 51 mmol/ L on January 31,2013. It was considered that the cetuximab induced hypomagnesemia. An intravenous infusion of magnesium sulfate 10 ml plus 0. 9% sodium chloride 500 ml once daily was given. On day 3,the blood magnesium was 0. 54 mmol/ L,and cetuximab 447. 5 mg was given,he was discharged. Magnesium sulfate was given in outpatient clinic. Eight days later,his blood magnesium was 0. 82 mmol/ L.